Ligand Buys Into Ongoing Partnerships With Icagen Deal

 
• By Joseph Haas

Ligand gets ongoing drug development collaborations with Roche and CFF, six novel preclinical compounds and sodium ion channel technology platform capabilities in acquiring Icagen’s North Carolina operations.

Perfect business partnership as a connecting puzzle shaped as two trees in the form of human heads connecting together as a corporate success metaphor for cooperation and agreement as equal partners.
Ligand says Icagen assets will enhance its business model, yield revenue

More from Deals

More from Business